Screening for benzodiazepines is an important component of many drug testing programs. Current immunochemical methods are limited by a lack of sensitivity to many of the 35 forms of benzodiazepines available and because the antibodies used are insensitive to the glucuronic acid conjugates that constitute the major metabolites in urine. The Triage TM Panel for Drugs of Abuse (Biosite Diagnostics), a new screening device, is a competitive immunoassay containing monoclonal antibodies directed against glucuronide metabolites of benzodiazepines. We tested this device on 326 urine specimens, which were also tested by two other immunoassay methods (FPIA and EMIT e) and by GC/MS. We found a sensitivity of 97.5% and a specificity of 94.3% for the Triage assay when it was applied to a population in which approximately 50% of the specimens were positive; a distribution of eight different benzodiazepines was found in the positive samples. Other immunoassays performed with lower sensitivity or specificity or both. We found no significant difference between two analysts using the Triage test. We conclude that the Triage method represents a superior method for benzodiazepine screening when compared with other immunoassay methods.
Introduction
The ability to detect benzodiazepines is an important component of many drug screening programs. These widely prescribed medications are subject to abuse, which can also lead to overdose, making reliable detection vital to clinical and many forensic screening programs.
It is unfortunate from a laboratory perspective that the array of benzodiazepine compounds in clinical use has mushroomed in recent years. Worldwide, over 35 compounds are available for prescription. The older members of this class--diazepam, oxazepam, and chlordiazepoxide--are usually prescribed in daily doses more than twice that of the newer compounds, such as lorazepam and alprazolam.
Complex metabolism adds another dimension to this analytical maze. For most benzodiazepines, only a small proportion of the parent drug is excreted unchanged. In most cases, ingestion of one drug leads to excretion of a family of metabolites with varying pharmacological potency. Many metabolites are conjugated at either the 1-or 3-position of the heterocyclic ring with glucuronic acid and excreted as glucuronide conjugates. Several authors (1) (2) (3) (4) have shown that antisera used in common immunochemical screening tests cannot recognize the glucuronide metabolites of the majority of the benzodiazepines, resulting in false negative screening tests; hydrolysis of the urine specimen with ~-glucuronidase prior to screening improved the sensitivity of these methods.
Recently, Biosite Diagnostics (San Diego, CA) has introduced Triage TM Panel for Drugs of Abuse, a new, rapid screening device for detection of seven drug classes in urine. The test is a competitive immunoassay employing monoclonal antibodies. During the primary immunological reaction, drugs or drug metabolites compete for antibody binding sites in solution with drugs or drug metabolites conjugated to colloidal gold particles. After a 10-min incubation, if a drug that is detected by the device is present at or above the threshold concentration, the antibodies will bind the drug, thus leaving the colloidal gold--drug conjugate (drug conjugate) free in solution. The reaction mixture is transferred to the drug detection area where monoclonal antibodies for each drug class are immobilized in discrete zones. These monoclonal antibodies bind any free drug conjugate, producing a distinct red bar after the membrane is clarified by the addition of three drops of a wash solution. For benzodiazepines, visual detection of the resultant colored band is reliably achieved at a limit of detection of 300 ng/mL. The procedure requires approximately 10 minutes for completion.
Unlike traditional screening immunoassays for benzodiazepines, the benzodiazepine test in the Triage Panel for Drugs of Abuse was designed to detect the glucuronide conjugates of two broad classes of benzodiazepines. The first class includes those benzodiazepines that are conjugated to glucuronic acid or contain a large functional group at the 1-position on the heterocyclic seven-membered ring. This class includes flurazeparn (~-hydroxyethylflurazepam), triazolam, alprazolam, midazolam, and nordiazepam. The second class represents the class of benzodiazepines that are conjugated with glucuronic acid via the hydroxyl group at the 3-position on the heterocyclic seven-membered ring. This class includes chlordiazepoxide, chlorazepate, oxazepam, temazepam, lorazepam, desalkyflurazepam, and diazepam. The monoclonal antibodies incorporated into the test were selected to react with the glucuronide conjugates of the ben-zodiazepines by selecting only those antibodies that reacted with a panel of patient urine specimens containing various benzodiazepine conjugates; these antibodies exhibited substantially less reactivity with the same urine specimens that were hydrolyzed using 13-glucuronidase. This results in a test for benzodiazepines that recognizes the urinary metabolites (e.g., lorazepam glucuronide) of the benzodiazepines and to a lesser extent the native compound or the unconjugated metabolite (e.g., lorazepam).
Because the technology in the Triage device appeared to offer a significant advance in screening for benzodiazepines, we evaluated the test with urine specimens that were prescreened for the presence or absence of benzodiazepines.
Materials and Methods

Study design
From specimens submitted to our laboratory for routine drug screening, we selected approximately equal numbers of specimens found negative and positive for benzodiazepines by either enzyme multiplied immunoassay (EMITS; Syva Co., Palo Alto, CA) or fluorescence polarization immunoassay (FPIA; Abbott Diagnostics, North Chicago, IL). It is noteworthy that the majority of the positive specimens selected in this study were selected to be positive by the EMIT benzodiazepine test. Some specimens had been stored frozen. A total of 326 specimens were tested; for a few, specimen volume was insufficient to perform all methods. A representative of Biosite Diagnostics trained two experienced analysts in the proper use of the Triage assay system. The analysts independently tested all specimens in a randomized manner. EMIT and FPIA test results were unknown to the analysts prior to performing the Triage assays. Triage results were recorded as positive or negative based on visual examination for the presence or absence of a red bar corresponding to the benzodiazepine test zone.
After completion of all Triage analyses, specimens were analyzed at Biosite Diagnostics for benzodiazepines using gas chromatography/mass spectrometry (GC/MS). All comparisons of the immunoassay screening methods to the GC/MS method were performed with a cutoff of 300 ng/mL for total benzodiazepines, that is, the sum of all benzodiazepine metabolites detected by GC/MS for each specimen. Those specimens that contained total benzodiazepine concentrations below 300 ng/mL and produced a positive screening result were designated as false positive. Similarly, those specimens that contained total benzodiazepine concentrations above 300 ng/mL and produced a negative screening result were designated as false negative.
Reagents
The standards used in the GC/MS analysis of benzodiazepines and benzodiazepine metabolites were ct-hydroxyalprazolam and (~-hydroxytriazolam (The Upjohn Company, Kalamazoo, MI), oxazepam, desalkylflurazepam, nordiazepam, lorazepam, and temazepam (Alltech-Applied Science, State College, PA), and (xhydroxyethylflurazepam (Hoffman LaRoche, Nutley, N J); these standards were either provided as a 1-mg/mL solution in methanol or diluted in methanol to 1 mg/mL. Gluronide conjugates of temazepam and c~-hydroxyalprazolam were synthesized enzymatically using 5'-diphosphoglucuronyl transferase and purified using high-performance liquid chromatography. The working standard containing all the benzodiazepines and benzodiazepine metabolites was prepared to contain 50 lag of each per milliliter of methanol Methaqualone was used as the internal standard (Alltech-Applied Science).
Bis(trimethylsilyl)trifluoroacetamide (BSTFA; Aldrich Chemical, Milwaukee, WI) was used to derivatize the benzodiazepines. ~-Glucuronidase (approximately 5000 U/mg, E.C. 3.2.1.31, Type L-I1 from Limpets) was obtained from Sigma Chemical (St. Louis, MO). 150  50  0  240  80  40  270  90  70  300  100  90  330  110  100  36O  120  100  450 150 100 9 The concentrations were calculated based on the nonglucuronide portion of the molecule.
Gas chromatography/mass spectrometry GC/MS was performed using a modification of the procedures published by Mul6 and Casella (5), Langer et al. (6), Dickson et al. (7), and Fraser et al. (8) . Two milliliters of urine plus 800 p_L 0.1M potassium phosphate buffer (pH 6.0) plus 400 /~L of 13-glucuronidase in 0. l M potassium phosphate (pH 6.0) at a concentration of 5 mg/mL (approximately 5000 U/rag; pH 5.0-7.0) was the reaction mixture used to hydrolyze the glucuronic acid from the "parent drug" for 4 h at 55~ After hydrolysis, the internal standard was added to each specimen, calibrator, and control. The hydrolyzed benzodiazepines and benzodiazepine metabolites were extracted from the urine using Bond Elut Certify columns (Varian, Harbor City, CA), eluted with ethyl acetate containing 3% ammonium hydroxide, and dried under dry argon at 30-40~ The extract was derivatized for 15 min at 90~ using 50 I.tL BSTFA. The derivatized drugs were further diluted with 50 gL ethyl acetate. This extract was analyzed using GC/MS.
A Hewlett-Packard (HP) 5890 gas chromatograph operated in the splitless mode was connected to an HP 5970 mass selective detector. An HP-1 column (12 m x 0.2-mm i.d., 0.33-gin film thickness) was used to separate each of the benzodiazepine derivatives and the internal standard. Quantitative analysis of the drugs was performed using the selected ion monitoring mode for each drug metabolite. Target ions for benzodiazepine metabolites are listed in Table I .
Precision
The precision, or analytical reproducibility, of the Triage Panel for Drugs of Abuse was evaluated using replicate determinations of the benzodiazepine glucuronide standards, temazepam glucuronide and (x-hydroxyalprazolam glucuronide. Each standard was evaluated at 10% increments, starting at 80% of the cutoff concentration up to 120% of the cutoff in replicates of 10. An additional five replicate determinations were made at 50% and 150% of the cutoff.
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A surmnary of the parent compounds of the benzodiazepine metabolites that are identified by the GC/MS procedure in the positive specimens is presented in Table IV .
Test results for the Triage test and GC/MS assays are summarized in Table V . Our study showed excellent agreement between the two analysts. In addition, we found a high degree of concordance between the Triage screening result and the GC/MS confirmatory assay. Collectively, these results suggest a sensitivity of 97.5% and a specificity of 94.3% for the Triage assay, when applied to a population in which approximately 50% of the specimens are positive.
EMIT and FPIA assay results appear in Table VI . The EMIT assay lacked specificity: More than one in four EMIT positive results could not be confirmed by GC/MS, using a total cutoff concentration of 300 ng/mL. Additionally, the EMIT assay produced more than 3 times as many false negative results as the Triage assay.
The FPIA method lacked sensitivity: Nearly one in four positive specimens tested negative with the FPIA assay. The FPIA assay had essentially the same specificity as the Triage test.
Statistical analysis of the sensitivity and specificity of all three methods using the t test (10) produced the following results (p<0.05): For sensitivity, the Triage performed better than EMIT, which performed better than FPIA for benzodiazepines. The higher sensitivity observed using the EMIT test as compared with the FPIA is probably due to the fact that the majority of the positive specimens in this study were initially screened using the EMIT test. Therefore, theoretically, the EMIT test should have been 100% sensitive compared with GC/MS, and only the specificity should have been compromised in this study. For speci-
Results
The capability of the Triage test to reproducibly detect temazepam and cz-hydroxyalprazolam near the claimed cutoff is demonstrated in Tables II and III . Results are presented as the percentage of samples tested at each concentration that were visually found positive. At the 300-ng/mL cutoff, the assay exhib- ficity, the Triage test was statistically equal to FPIA, and both performed better than EMIT for benzodiazepines. A summary of apparent false negative and apparent false positive specimens from the Triage Panel for Drugs of Abuse are shown in Tables VII and VIII, Fraser (3) found that both FPIA and EMIT identified most cases of alprazolam ingestion. Fraser (9) has also shown that both assays are suitable for detection of midazolam ingestion but that the EMIT assay fails to identify Iriazolam in most subjects (8) .
Our findings, derived from randomly selected positive and negative specimens without prior knowledge of the specific benzodiazepines present, demonstrate that in routine practice the EMIT and FPIA assays are of limited value. The EMIT assay exhibited poor specificity, whereas the FPIA assay was insufficiently sensitive. The true sensitivity of the EMIT test cannot be accurately determined from this study because the majority (greater than 90%) of the positive specimens were selected based on positivity for benzodiazepines with the EMIT benzodiazepine test.
It is important to emphasize that our study design incorporated a much higher prevalence of positive cases than would be en- countered in any screening setting. With the percentage of positive cases typically observed in screening situations, one would expect even poorer diagnostic specificity than that exhibited here. The Triage assay exhibited markedly better diagnostic accuracy than both the EMIT and FPIA assays. Incorporation of monoclonai antibodies targeted against the glucuronide metabolites of benzodiazepines is the likely reason for this improved performance.
In our hands, the Triage assay exhibited no dependence on the analyst. We found the method reliable and reproducible. Even though the Triage test is simple to perform, it remains to be seen if unskilled, nonlaboratory personnel lacking specialized training can successfully use this test method. It also is uncertain what level of diagnostic sensitivity and specificity will be achieved in a typical screening setting, where positive cases are a small percentage. However, when considering the differences in test performance observed in this study, the Triage test should perform better than the other screening tests for benzodiazepines when applied to a typical population.
